Maxalt

Type: Product

Name: Maxalt

First reported Jun 18 2013 - Updated Jun 18 2013 - 2 reports

IntelGenx's anti-migraine VersaFilm before FDA in 2014

The U.S. Food and Drug Administration has assigned a Prescription Drug User Fee Act action date of Feb. 3, 2014, for the review of IntelGenx Corp.'s new drug application for the marketing approval of IntelGenx's anti-migraine VersaFilm oral film prod ... [Published Stockwatch - Jun 18 2013]

Entities: IntelGenx Technologies Corp, Maxalt, FDA Food & Drug Administration

First reported Jun 18 2013 - Updated Jun 18 2013 - 1 reports

REDHILL BIOPHARMA: FDA Sets Feb. 3 Goal Date to Review Generic Maxalt Application

RedHill Biopharma Ltd. (RDHL, RDHL.TV) and IntelGenx Technologies Corp. (IGXT, IGX.V) said the U.S. Food and Drug Administration accepted their new drug application for the experimental acute migraine treatment RHB-103 and has set a Feb. 3 target date ... [Published 4 Traders - Jun 18 2013]

Entities: RedHill Biopharma Ltd, Maxalt, FDA Food & Drug Administration, IntelGenx Technologies Corp, Merck & Co Inc

First reported Jun 04 2013 - Updated Jun 04 2013 - 1 reports

Singulair

Merck’s Shares Jump On New Clinical Trial Data

Like other major pharmaceutical companies, Merck (NYSE:MRK) is battling against the impact of patent expiry of its several major drugs including Singulair, Propecia, Clarinex, Maxalt, Cozaar and Hyzaar. Out of these, the impact on asthma drug Singulair ... [Published Trefis - Jun 04 2013]

Entities: Clinical trials, Singulair, Drugs, lambrolizumab

First reported May 22 2013 - Updated May 22 2013 - 1 reports

Merck & Co Inc

Merck Enters into Strategic Deal Zacks

In an attempt to boost shareholders’ value, Merck & Co. Inc. (MRK) – the N.J. based major drug manufacturer – entered into an agreement with The Goldman Sachs Group, Inc. (GS) to repurchase $5 billion of its shares. The deal comes under the $15 billion ... [Published Yahoo! Finance - May 22 2013]

Entities: Merck & Co Inc, Singulair, Stocks, Stock Prices, Goldman Sachs Group Inc

First reported May 22 2013 - Updated May 22 2013 - 3 reports

Goldman Sachs Group Inc

Merck to buy $5B in stock from Goldman Sachs in jump-start for repurchase plan

Merck CEO Kenneth FrazierGeneric competition, sales woes and R&D disappointments have put revenue on the decline and Merck ($MRK) in hot water, with the pharma giant earlier this month promising to buy back as much as $15 billion in shares. And yesterday, ... [Published FiercePharma - May 22 2013]

Entities: Goldman Sachs Group Inc, Drugs, Stocks, Research & Development

First reported Mar 27 2013 - Updated Mar 28 2013 - 2 reports

IntelGenx files NDA for Rizatriptan anti-migraine film

IntelGenx Corp., together with its co-development partner RedHill Biopharma, has submitted a 505(b)(2) new drug application to the U.S. Food and Drug Administration for the company's anti-migraine oral film product, a novel oral thin-film formulation ... [Published Stockwatch - Mar 27 2013]

Entities: IntelGenx Technologies Corp, Maxalt, New Drug Application

First reported Feb 26 2013 - Updated Feb 26 2013 - 1 reports

RIZATRIPTAN BENZOATEtablet, Orally Disintegrating [Physicians Total Care, Inc.]

Updated Date: Feb 26, 2013 EST ... [Published DailyMed Drug Label Updates for the last seven ... - Feb 26 2013]

Entities: Maxalt

First reported Feb 20 2013 - Updated Feb 20 2013 - 1 reports

RIZATRIPTAN BENZOATEtablet [Physicians Total Care, Inc.]

Updated Date: Feb 19, 2013 EST ... [Published DailyMed Drug Label Updates for the last seven ... - Feb 20 2013]

Entities: Maxalt

First reported Feb 19 2013 - Updated Feb 19 2013 - 1 reports

RIZATRIPTAN BENZOATEtablet [Physicians Total Care, Inc.]

Updated Date: Feb 19, 2013 EST ... [Published DailyMed Drug Label Updates for the last seven ... - Feb 19 2013]

Entities: Maxalt

First reported Feb 17 2013 - Updated Feb 17 2013 - 1 reports

MAXALT (Rizatriptan Benzoate) Tablet MAXALT-MLT (Rizatriptan Benzoate) Tablet, Orally Disintegrating [Merck Sharp Dohme Corp.]

Updated Date: Feb 14, 2013 EST ... [Published DailyMed Drug Label Updates for the last seven ... - Feb 17 2013]

Entities: Maxalt, Merck & Co Inc

First reported Feb 13 2013 - Updated Feb 14 2013 - 2 reports

RIZATRIPTAN BENZOATEtablet [Teva Pharmaceuticals USA Inc]

Updated Date: Feb 13, 2013 EST ... [Published DailyMed Drug Label Updates for the last seven ... - Feb 14 2013]

Entities: Maxalt, Teva Pharmaceutical Industries Ltd

First reported Jan 02 2013 - Updated Jan 02 2013 - 2 reports

RIZATRIPTAN BENZOATEtablet RIZATRIPTAN BENZOATEtablet, Orally Disintegrating [Par Pharmaceutical Inc.]

Updated Date: Jan 2, 2013 EST ... [Published DailyMed Drug Label Updates for the last seven ... - Jan 02 2013]

Entities: Maxalt, Par Pharmaceutical

Quotes

"We are excited about the possibility of bringing RHB-103 to the market as an attractive new treatment option for physicians and for migraine sufferers who may benefit from the significant potential advantages of RHB-103, such as rapid dissolution, ease of use, pleasant flavoring, and the ability to administer without water" said Elkan Gamzu, RedHill's RHB-103 product manager

REDHILL BIOPHARMA: FDA Sets Feb. 3 Goal Date to Review Generic Maxalt Application [Published 4 Traders - Jun 18 2013]

...The film does not require water for administration. On announcing the news, IntelGenx President and CEO Dr. Horst Zerbe commented, "We are very pleased with the FDA's confirmation that our anti-migraine film application has been accepted for review. We believe that our Rizatriptan film is the first oral film product for the treatment of migraine for which a 505(b)(2) NDA has been submitted to FDA. We consider that the product has significant market potential as it is therapeutically equivalent to Maxalt-MLT® orally disintegrating tablets, is easy to use, and offers significant cost advantages over orally disintegrating tablets."

IntelGenx's anti-migraine VersaFilm before FDA in 2014 [Published Stockwatch - Jun 18 2013]

"This accelerated share repurchase demonstrates our commitment to delivering increased value to shareholders in the short term, while continuing to invest in the important opportunities that will drive our long-term growth" CEO Kenneth Frazier said in a statement

Merck to buy $5B in stock from Goldman Sachs in jump-start for repurchase plan [Published FiercePharma - May 22 2013]

"Get ValueWalk's Daily Edition By Email and Never Miss Our Top Stories"

Merck To Repurchase $5B Shares From Goldman Sachs [Published Value Walk - May 22 2013]

More Content

sort by: Date \| Relevance
Jane M. Teunissen [Published Ozaukee Press - 6 hours ago]
Daniel J. ‘Red’ Nielsen [Published Ozaukee Press - 6 hours ago]
Honduran Politicians' Aversion to Writing [Published Hondurasweekly - Jun 18 2013]
REDHILL BIOPHARMA: FDA Sets Feb. 3 Goal Date to... [Published 4 Traders - Jun 18 2013]
RedHill Says FDA Accepts NDA For Marketing Migr... [Published RTTNews.com - Jun 18 2013]
IntelGenx's anti-migraine VersaFilm before FDA ... [Published Stockwatch - Jun 18 2013]
IntelGenx Announces FDA Acceptance of New Drug ... [Published Stockwatch - Jun 18 2013]
AMD’s SeaMicro SM15000 Server Achieves Certific... [Published AMD Zone - Jun 14 2013]
Battlefield 4 Optimized For Radeon, AMD APUs, FX [Published AMD Zone - Jun 13 2013]
Is Merck the Best Option In This Group? [Published Wall St. Cheat Sheet - Jun 13 2013]
Daniel Grotkiewicz [Published Ozaukee Press - Jun 13 2013]
Wilbert Klapperich [Published Ozaukee Press - Jun 13 2013]
Drug Solubility Technology: Spray Drying, Extru... [Published Individual.com - Jun 12 2013]
Merck's Shares Perk Up On Cancer Drug Clinical ... [Published Nasdaq - Jun 11 2013]
Jorge Montenegro's "Humorous Stories" [Published Hondurasweekly - Jun 10 2013]
AMD’s Nicholas Thiebierroz Interviewed [Published AMD Zone - Jun 07 2013]
Gertrude “Trudi” M. Bloecher [Published Ozaukee Press - Jun 05 2013]
Hattie J. Peiffer [Published Ozaukee Press - Jun 05 2013]
Patricia Kotecki [Published Ozaukee Press - Jun 05 2013]
Ervin W. Schlenvogt [Published Ozaukee Press - Jun 05 2013]
Merck’s Shares Jump On New Clinical Trial Data [Published Trefis - Jun 04 2013]
The Dope On A Forest Labs Takeover [Published Seeking Alpha - Jun 04 2013]
Carl P. Dever Jr. [Published Ozaukee Press - May 30 2013]
Faye Brown [Published Ozaukee Press - May 30 2013]
The Dope On a Forest Labs Takeover [Published YCharts - May 30 2013]
AMD Releases Catalyst 13.6 Beta Driver [Published AMD Zone - May 30 2013]
Merck Enters into Strategic Deal Zacks [Published Yahoo! Finance - May 22 2013]
Merck to buy $5B in stock from Goldman Sachs in... [Published FiercePharma - May 22 2013]
Merck To Repurchase $5B Shares From Goldman Sachs [Published Value Walk - May 22 2013]
Merck signs $5 bln share buyback agreement with... [Published Reuters - May 22 2013]

sort by: Date \| Relevance
IntelGenx Submits New Drug Application for Anti... [Published GlobeNewswire: Acquisitions News - Mar 27 2013]
Par Pharmaceutical Begins Shipment of Rizatript... [Published PR Newswire: General Business - Jan 02 2013]
Mylan Launches First Generic Maxalt MLT® Tablets [Published PR Newswire: Policy & Public Interest - Jan 02 2013]
Breckenridge Announces Approval of Rizatriptan ... [Published PR Newswire: Policy & Public Interest - Dec 30 2012]
Glenmark Generics Receives Tentative Approval f... [Published PR Newswire - Sep 20 2012]